Sign in
MGNX Stock Price, Chart, Stats & News
MacroGenics, Inc.
Save
251.71M
Market cap
–
Current P/E
60.98x
Forward P/E
MGNX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 71.12% |
Operating margin | -48.72% |
Pretax margin | -50.36% |
Net margin | -49.91% |
Effective tax rate | 0.89% |
ROA | -29.05% |
ROE | -120.20% |
D/E | 1.92x |
Interest coverage ratio | -8.56x |
MGNX valuation
P/E | – |
P/S | 1.25x |
P/B | 3.33x |
P/CF | -2.28x |
P/FCF | -2.24x |
P/OCF | -2.28x |
PEG | -0.99x |
EV multiple | -2.08x |
About
MacroGenics, Inc. is a U. S.-based biopharmaceutical company specializing in the development and commercialization of antibody-derived treatments primarily aimed at combating cancer. The company's sole approved product is MARGENZA (margetuximab-cmkb).
Similar securities
Based on sector and market capitalization
Report issue